Novavax vs Moderna Which Should You Buy?

Novavax and Moderna are two pharmaceutical companies that have been in the spotlight in recent times due to their development of COVID-19 vaccines. Both companies have seen a surge in their stock prices as a result of their promising vaccine candidates. Novavax's stock has experienced significant volatility, while Moderna's stock has been relatively more stable. Investors are closely watching both companies as they compete to bring effective vaccines to market and navigate the evolving landscape of the biotech industry.

Novavax or Moderna?

When comparing Novavax and Moderna, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Novavax and Moderna.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Novavax has a dividend yield of -%, while Moderna has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Novavax reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Moderna reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Novavax P/E ratio at -5.12 and Moderna's P/E ratio at -7.24. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Novavax P/B ratio is -2.77 while Moderna's P/B ratio is 1.35.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Novavax has seen a 5-year revenue growth of 4.26%, while Moderna's is 10.87%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Novavax's ROE at 44.82% and Moderna's ROE at -17.68%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $8.88 for Novavax and $41.38 for Moderna. Over the past year, Novavax's prices ranged from $3.53 to $23.86, with a yearly change of 575.92%. Moderna's prices fluctuated between $35.80 and $170.47, with a yearly change of 376.17%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.